Paid Clinical Trials Memphis
Discover 562 paid clinical trials in Memphis, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Percutaneous InterventionPercutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
Sponsor:
Nationwide Children's Hospital
Location:
Code:
NCT05547165
Conditions
Ductus Arteriosus, Patent
Eligibility Criteria
Sex: All
Age: 7 - 32
Healthy Volunteers: Not accepted
Interventions
Percutaneous Patent Ductus Arteriosus Closure (PPC)
Responsive Management Intervention
Echocardiogram, cardiac
LurbinectedinStudy of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Sponsor:
Jazz Pharmaceuticals
Location:
Code:
NCT05734066
Conditions
Refractory Ewing Sarcoma
Relapsed Ewing Sarcoma
Ewing Sarcoma
Eligibility Criteria
Sex: All
Age: 2 - 30
Healthy Volunteers: Not accepted
Interventions
Lurbinectedin
LP352A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Sponsor:
Longboard Pharmaceuticals
Location:
Code:
NCT06908226
Conditions
Developmental and Epileptic Encephalopathy
Eligibility Criteria
Sex: All
Age: 2 - 66
Healthy Volunteers: Not accepted
Interventions
LP352
BHV-7000Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Sponsor:
Biohaven Therapeutics Ltd.
Location:
Code:
NCT06309966
Conditions
Focal Epilepsy
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BHV-7000
Placebo
Observational StudyFeasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
Sponsor:
St. Jude Children's Research Hospital
Location:
Code:
NCT06480526
Conditions
High-risk Neuroblastoma
Eligibility Criteria
Sex: All
Age: 5+
Healthy Volunteers: Not accepted
EtavopivatA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Sponsor:
Novo Nordisk A/S
Location:
Code:
NCT06609226
Conditions
Sickle Cell Disease, Thalassemia
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Etavopivat A
Etavopivat B
BIIB091 & DRFA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
Sponsor:
Biogen
Location:
Code:
NCT05798520
Conditions
Relapsing Forms of Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
BIIB091
DRF
Placebo
PegozaferminA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Sponsor:
89bio, Inc.
Location:
Code:
NCT06419374
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Pegozafermin
Placebo
Radiation Therapy with AtezolizumabStudy of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04310020
Conditions
Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Biospecimen Collection
Computed Tomography
Hypofractionated Radiation Therapy
Magnetic Resonance Imaging
Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05455320
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Talquetamab
Daratumumab
Pomalidomide
Dexamethasone